Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Authors:
- A. N. BoykoABA. N. Boyko
- M. N. ZakharovaMZM. N. Zakharova
- T. O. SimanivTST. O. Simaniv
- V. M. AlifirovaVAV. M. Alifirova
- E. G. ArefievaEAE. G. Arefieva
- M. A. BarabanovaMBM. A. Barabanova
- Z. A. GoncharovaZGZ. A. Goncharova
- I. V. GreshnovaIGI. V. Greshnova
- V. A. DudinVDV. A. Dudin
- D. S. KorobkoDKD. S. Korobko
- S. V. KotovSKS. V. Kotov
Open Access
- 23 August 2025
- journal article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Abstract
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.Keywords
This publication has 31 references indexed in Scilit:
- Correction: Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum DisorderNeurology and Therapy, 2024
- Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapiesRevue Neurologique, 2024
- Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum DisorderAnnals of Neurology, 2023
- Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016–2021Journal of Cancer Policy, 2023
- Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialEBioMedicine, 2022
- AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderMultiple Sclerosis and Related Disorders, 2022
- Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and MycophenolateNeurology and Therapy, 2021
- The Use of External Controls in FDA Regulatory Decision MakingTherapeutic Innovation & Regulatory Science, 2021
- Confidence intervals for ratio of two Poisson rates using the method of variance estimates recoveryComputational Statistics, 2013
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)Journal of Neurology, 2013